Merck Loses Appeal To Extend Protections For MS Drug
Merck cannot extend its patent protection for a multiple sclerosis treatment because earlier marketing authorizations cover the same drug, a London appeals court ruled on Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article